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Abstract
The rate of co-dependency for alcohol and nicotine is extremely high. Numerous studies have
indicated that there is a common genetic association for alcoholism and nicotine dependency. The
current experiments examined whether selective breeding for high alcohol preference in rats may
be associated with increased sensitivity of the posterior ventral tegmental area (pVTA) to the
reinforcing properties of nicotine. In addition, nicotine can directly bind to the serotonin-3 (5-HT3)
receptor, which has been shown to mediate the reinforcing properties of other drugs of abuse
within the pVTA Wistar rats were assigned to groups that were allowed to self-infuse 0, 10, 50,
100, 200, 400 or 800 μM nicotine in 2-lever (active and inactive) operant chambers. P rats were
allowed to self-infuse 0, 1, 10, 50 or 100 μM nicotine. Co-infusion of 5-HT3 receptor antagonists
with nicotine into the pVTA was also determined. P rats self-infused nicotine at lower
concentrations than required to support self-administration in Wistar rats. In addition, P rats
received more self-infusions of 50 and 100 μM nicotine than Wistar rats. Including a 5HT3
receptor antagonist (LY-278,584, or zacopride) with nicotine reduced responding on the active
lever. Overall, the data support an association between selective breeding for high alcohol
preference and increased sensitivity of the pVTA to the reinforcing properties of nicotine. In
addition, the data suggest that activation of 5HT3 receptors may be required to maintain the local
reinforcing actions of nicotine within the pVTA.
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INTRODUCTION
Epidemiological and clinical studies estimate that 80-95% of alcohol-dependent individuals
are regular smokers (Hurt et al., 1994; Pomerleau, Aubin, and Pomerleau, 1997; Romberger
and Grant, 2004). Alcohol dependent individuals also have higher rates of nicotine
dependence (Hughes, Rosa, and Callas, 2000; Room, 2004). Alcohol intake is also
significantly higher in nicotine users than alcohol users alone (York and Hirsch, 1995;
Williamson et al., 1997). Common genetic factors may make certain individuals vulnerable
to both alcohol and smoking addiction (Carmelli, Swan, and Robinette, 1993; Enoch and
Goldman, 2001; Swan, Carmelli, and Cardon, 1997). Twin studies show that there may be a
genetic linkage between alcohol dependence and nicotine dependence (True et al., 1999;
Volk et al., 2007; Nurnberger et al., 2004).
The selectively bred alcohol-preferring (P) line of rat has been well characterized both
behaviorally and neurobiologically and satisfies criteria proposed as essential for an animal
model of alcoholism (reviewed in McBride and Li 1998; Murphy et al. 2002). Behavioral
pharmacological studies demonstrated that ethanol (EtOH) discriminative stimulus
generalizes to nicotine in P rats compared to NP rats (Gordon, Meehan, and Schechter,
1993; McMillan, Li, and Shide, 1999) and that P rats are more likely to substitute nicotine
for EtOH (McMillan et al., 1999). Le at al. (2006) findings showed that EtOH-naïve P rats
will intravenously (i.v.) self-administer more nicotine and express greater nicotine-seeking
behavior than NP rats. The Le et al. (2006) findings with P rats provide support for the
hypothesis that nicotine and alcohol addiction may share common genetic vulnerabilities.
Mice selected for differential sensitivity to the locomotor stimulatory effects of EtOH
(FAST and SLOW) are also differentially affected by nicotine. FAST mice are more
responsive to nicotine than SLOW mice (Bergstrom et al., 2003). Furthermore, reverse
selection of FAST and SLOW mice (breeding FAST mice with mice that were not
responsive to EtOH, and SLOW to EtOH-responsive mice) reduced the enhanced locomotor
stimulatory profile in FAST mice, while producing an enhancement in SLOW mice
(Bergstrom et al., 2003).
Nicotinic receptors are present in the ventral tegmental area (VTA) and the reinforcing
effects of nicotine are mediated mainly via stimulation of nicotinic receptors within the VTA
(Corrigall, Coen, and Adamson, 1994; Nisell, Nomikos, and Svensson, 1994). The
reinforcing effects of EtOH are thought to be partially mediated by central nicotinic
receptors (Blomqvist et al., 1996; Ericson et al., 2003; Soderpalm et al., 2000) and EtOH can
elevate dopamine levels via indirect activation of nicotinic receptors (Ericson et al., 2003).
In the P rat, systemic administration of nicotine can increase both EtOH-seeking and EtOH
relapse drinking in a time dependent manner (Hauser et al., 2012).
Nicotine can increase the firing rate of dopaminergic (DA) neurons (Grenhoff, Aston-Jones,
and Svensson, 1986) and enhance somatodendritic DA release in the VTA (Rahman, Zhang,
and Corrigall 2003; 2004). In addition, nicotine can increase the release of DA in the
nucleus accumbens (Yoshida et al., 1993; Nisell et al., 1994; Ferrari et al., 2002; Tizabi et
al., 2002).
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The VTA appears to be involved in mediating i.v. nicotine self-administration (Corrigall et
al., 1994). The posterior (but not the anterior) VTA is a neuroanatomical site supporting the
reinforcing actions of both EtOH (Rodd et al., 2004; Rodd-Henricks et al., 2000) and
nicotine (Ikemoto, Qin, and Liu, 2006). There is evidence that genetic factors influence the
reinforcing actions of EtOH within the VTA, with an association between selective breeding
for alcohol preference and enhanced sensitivity of the posterior VTA to the reinforcing
effects of EtOH (Rodd et al., 2004).
The reinforcing effects of nicotine within the posterior VTA were blocked by the co-
infusion of mecamylamine, a nicotinic receptor antagonist (Ikemoto et al., 2006). Previous
studies indicated that the self-infusions of EtOH (Rodd-Henricks et al., 2003) and cocaine
(Rodd et al., 2005a) into the posterior VTA were inhibited with the co-infusion of
serotonin-3 (5-HT3) receptor antagonists. In addition, a 5-HT3 receptor agonist was self-
infused by P and Wistar rats into the posterior VTA, supporting the idea that local activation
of 5-HT3 receptors can produce rewarding effects.
Nicotine is not specific for cholinergic receptors. In fact, nicotine binds at a lower affinity to
the 5-HT3 receptors than any cholinergic nicotinic receptors (c.f., Jackson and Yakel, 1995;
Breitinger, Geetha, and Hess, 2001; Gurley and Lanthorn, 1998). Originally, the 5-HT3
receptor was classified as a nicotinic acetylcholine receptor (NAchR; Jackson and Yakel,
1995). The increase in the affinity of CNS acetylcholine receptors to nicotine compared to
acetylcholine receptors in the periphery (muscle) is predicated upon a cation-π interaction
(Xiu et al., 2008). The 5-HT3 receptor also has a cation-π interaction that enhances its
affinity for nicotine (Beene et al., 2002). In fact, the NAchRs are sensitive to a reduction in
affinity for nicotine following point mutations, while the cation-π interaction in the 5-HT3
receptor is resistant to the loss of affinity to nicotine following point mutations (Beene et al.,
2002).
Agonist and antagonist for the NAchRs are not specific. The NAchR agonist (epibatidine)
and antagonist (mecamylamine) have at least a 4-fold greater affinity for the 5-HT3 receptor
than the NAchR (Drisdel et al., 2008). In contrast, 5-HT3 receptor antagonists (LY-278,584
and Zacopride) do not have an appreciable affinity for nicotinic receptors (Macor et al.,
2001; Kidd et al., 1993). Specificity of antagonists for NAchRs and 5-HT3 receptors are
further complicated by the observation that these two receptors can co-assemble. The α4
NAchR subunit can co-assemble with the 5-HT3 receptor to produce a heteromeric 5-HT3
receptor channel with enhanced Ca permeability and a decrease in sensitivity to the ability
of antagonists to block activation of the novel receptor (van Hooft et al., 1998).
Because of the similarities in structure between nicotinic and 5-HT3 receptors (Mascia,
Trudell, and Harris, 2000; Peters et al., 2006), and the potential interactions of these
receptors and of nicotine at the 5-HT3 receptor (Bianchi et al., 1995; Gurley and Lanthorn
1998; Nayak et al., 2000; Dougherty and Nichols 2009), it is possible that the reinforcing
effects of nicotine within the posterior VTA may be mediated in part through activation of
5-HT3 receptors.
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The objectives of the present study were to test the hypotheses that (a) the posterior VTA of
the P rat is more sensitive than the posterior VTA of Wistar rats to the reinforcing effects of
nicotine, and (b) the reinforcing actions of nicotine within the posterior VTA are mediated in
part by activation of 5-HT3 receptors.
MATERIALS AND METHODS
Animals
Female alcohol-naïve Wistar rats (Harlan, Indianapolis, IN) and P rats (52nd and 53rd
generations) weighing 250-320 g at time of surgery were used. Female rats were used in the
present study because (a) they were used in the initial and previous studies (Gatto et al.
1994; Rodd-Henricks et al. 2000, 2003), and (b) they maintain their body weights and head
size better than male rats for more accurate stereotaxic placements. The estrous cycle was
not monitored in the present study. However, counterbalanced experiments were conducted
on different days so that any effect of a given phase of the estrous cycle was distributed
across experimental conditions. Animals were double-housed upon arrival and were
maintained on a 12-hr reverse light-dark cycle (lights off at 0900 hr). Food and water were
freely available except in the test chamber. All research protocols were approved by the
Institutional Animal Care and Use Committee and are in accordance with the guidelines of
the Institutional Animal Care and Use Committee of the National Institute on Drug Abuse,
NIH, and the Guide for the Care and Use of Laboratory Animals (National Research Council
1996).
Data for rats that did not complete all experimental test sessions were eliminated from the
analyses. The number of animals indicated for each experiment represents approximately
85% of the total number that underwent surgery; 15% of the animals were not included for
analyses mainly due to the loss of the guide cannula before completion of all experimental
sessions. The data for these animals were not used because their injection sites could not be
verified.
Drug and Vehicle
The artificial cerebrospinal fluid (aCSF) vehicle consisted of (in mM): 120.0 NaCl, 4.8 KCl,
1.2 KH2PO4, 1.2 Mg SO4, 25.0 NaHCO3, 2.5 CaCl2, and 10.0 d-glucose. Nicotine tartrate
(Sigma-Aldrich, St. Louis, MO USA), LY-278,584 (Eli Lilly Company, Indianapolis, IN,
USA) and zacopride (Tocris Bioscience, Ellisville, MO) were dissolved in aCSF. When
necessary, 0.1 M HCl or 0.1 M NaOH was added to the solutions to adjust the pH to 7.4 +
0.1.
Apparatus
Standard 2-lever operant chambers (previously described: Rodd-Henricks et al., 2003; Rodd
et al., 2004) were situated in sound-attenuating cubicles ( Coulbourn Instruments,
Allentown, PA) which were illuminated by a dim house-light during testing. Two identical
levers were mounted on a single wall of the test chamber, 15 cm above a grid floor, and
were separated by 12 cm. Levers were raised to this level to avoid accidental brushing
against the lever and to reduce responses as a result of locomotor activation. Directly above
Hauser et al. Page 4
Addict Biol. Author manuscript; available in PMC 2015 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
each lever was a row of three different colored cue lights. The light (red) to the far right over
the active bar was illuminated during resting conditions. A desktop computer equipped with
an operant control system (L2T2 system, Coulbourn Instruments) recorded the data and
controlled the delivery of infusate in relation to lever response.
An electrolytic microinfusion transducer (EMIT) system, as previously described (Rodd-
Henricks et al. 2003; Rodd et al. 2004) was used to control microinfusions of nicotine or
vehicle. Depression of the active lever delivered the infusion current for 5 sec, which led to
the rapid generation of H2 gas (raising the pressure inside the airtight cylinder), and, in turn,
forcing 100 nl of the infusate through the injection cannula. During the 5-sec infusion and
additional 5-sec timeout period, the house light and right cue light (red) were extinguished
and the left cue light (green) over the active lever flashed on and off at 0.5 sec intervals.
Animal Preparation
While under isoflurane anesthesia, a unilateral 22-gauge guide cannula (Plastics One) was
stereotaxically implanted in the right hemisphere of each subject and, aimed 1.0 mm above
the target region. Coordinates for placements into the pVTA were 5.4 to 6.0 mm posterior to
bregma, 2.1 mm lateral to the midline, and 8.5 mm ventral from the surface of the skull at a
10° angle to the vertical. In between experimental sessions, a 28- gauge stylet was placed
into the guide cannula and extended 0.5 mm beyond the tip of the guide. Following surgery,
all rats were individually housed and allowed to recover 7-10 days. Animals were handled
for at least 5 min daily following the fourth recovery day. Subjects were not acclimated to
the test chamber prior to the commencement of data collection, nor were they trained on any
other operant paradigm.
General Test Conditions
For testing, subjects were brought to the testing room, the stylet was removed, and the
injection cannula screwed into place. Rats were placed individually in the test chamber. To
avoid trapping air at the tip of the injection cannula, the infusion current was delivered for 5
sec during insertion of the injector that resulted in a non-contingent administration of
nicotine or aCSF at the beginning of the session. Injection cannulae extended 1.0 mm
beyond the tip of the guide. The test chamber was equipped with two levers. Depression of
the ‘active lever’ (FR1 schedule of reinforcement) caused the delivery of a 100-nl bolus of
infusate over a 5-sec period followed by a 5-sec time-out period. During both the 5-sec
infusion period and 5-sec time-out period, responses on the active lever did not produce
further infusions. The assignment of active and inactive lever with respect to the left or right
position was counterbalanced among subjects. However, the active and inactive levers
remained the same for each rat throughout the experiment. No shaping technique was used
to facilitate the acquisition of lever responses. The number of infusions and responses on the
active lever was recorded. Responses on the ‘inactive lever’ were recorded, but did not
result in infusions. The duration of each test session was 4 hr and sessions occurred every
other day.
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Nicotine Self-Administration: Dose Response P vs. Wistar rats
Wistar (n = 6-10/group) and P (n = 5-7/group) rats were randomly assigned to one group to
receive aCSF or a given concentration of nicotine. Wistar rats were allowed to self-infuse 0 -
800 μM nicotine; P rats were given 0 – 100 μM nicotine. Wistar rats were allowed to self-
infuse higher nicotine doses than P rats to determine the maximal concentration of nicotine
for that strain. For P rats, the maximal concentration appeared to be around 50 – 100 μM
nicotine. The original infusate solution was available for self-administration during the first
four sessions (acquisition). During the fifth and sixth sessions (extinction), all animals
received infusions of aCSF. On the seventh session, rats were allowed to respond for their
originally assigned infusate.
Wistar rats were used instead of NP rats because previous ICSA studies indicated that NP
rats would not self-infuse EtOH over a range of 25 to 200 mg/100 ml concentrations (Gatto
et al. 1994). However, Wistar rats, using the ICSA technique will self-infuse EtOH
(Engleman et al. 2009; Rodd et al. 2004, 2005a; Rodd-Henricks et al. 2000), cocaine (Katner
et al. 2011), nicotine (Ikemoto et al. 2006) and other drugs (Rodd-Henricks et al. 2003;
Rodd et al. 2008) with no prior operant training, and within the limited number of injection
sessions required for ISCA procedure. In addition, P and NP rats were originally derived
from a colony of Wistar rats (Lumeng et al. 1977).
Co-infusion of 5-HT3 receptor antagonists with Nicotine
LY-278,584 and zacopride are two potent 5-HT3 antagonists that were selected because both
can block EtOH ICSA in pVTA at doses from 25–100 μM or 10–100 μM, respectively
(Rodd-Henricks et al. 2003). Wistar rats were randomly assigned to groups that self-
administered 200 μM nicotine for the initial 4 sessions, 200 μM nicotine containing 100 or
200 μM LY-278,584, or 10 or 100 μM zacopride (n = 6 - 8/dose) during session 5 and 6, and
200 μM nicotine alone during session 7.
Histology
At the termination of the experiment, 1% bromophenol blue (0.5 ul) was injected into the
infusion site. Subsequently, the animals were given a fatal dose of Nembutal (100 mg/kg)
and then decapitated. Brains were removed and immediately frozen at −70° C. Frozen brains
were equilibrated at −15° C in a cryostat microtome and then sliced into 40 um sections.
Sections were then stained with cresyl violet and examined under a light microscope for
verification of the injector site using the rat brain atlas of Paxinos and Watson (1998).
Statistical Analysis
Data analysis consisted of a group x day mixed ANOVA, with a repeated measure of session
performed on the number of infusions. Additionally, for each individual group, lever
discrimination was determined by type (active or inactive) x day mixed ANOVA with a
repeated measure of ‘session.’
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RESULTS
The pVTA was defined as the VTA region at the level of the interpeduncular nucleus,
coronal sections at −5.4 to −6.04 bregma (Fig. 1). Rats with injector tip placements outside
the VTA (i.e., substantia nigra, red nucleus, and caudal linear nucleus) displayed an overall
low level of infusions and active lever responding throughout all sessions (average infusions
and active lever responses for initial 4 sessions – 5.2 + 1.3 and 12.3 + 2.2, respectively). For
all sessions, the number of infusions of nicotine outside the VTA was not significantly
different than the aCSF group with injection sites in the VTA (p values > 0.53, data not
shown). Similarly, examination of the active lever responses revealed that rats administering
nicotine into areas outside the VTA displayed equivalent amounts of low levels of
responding on both the active and inactive levers (p values > 0.73, data not shown).
Nicotine Self-infusions: Dose Response P vs. Wistar rats
A mixed factor ANOVA performed on the number of self-infusions for each session with
between factors of nicotine concentrations (0, 10, 50 and 100 μM nicotine) and rat line (P vs
Wistar) revealed a significant session X nicotine concentration X rat line interaction (F18,
147 = 3.4; p < 0.001), a significant effect of nicotine concentration (F3, 52 = 19.2; p <
0.001) and rat line (F1,52 = 31.8; p < 0.001). Simplifying the analysis, by examining effects
of the between subject factors rat line and nicotine concentration on the average number of
self-infusions between session 1-4 (Fig. 2), similarly revealed a significant rat line x nicotine
concentration interaction (F3,52 = 6.7; p < 0.001). Examining the self-infusion of nicotine
within each line indicated that P rats self-administered nicotine at lower concentrations and
received more self-infusions than Wistar rats (Fig. 2).
For the P rat (including the 1 μM nicotine group), the analysis indicated a significant effect
of nicotine concentration (F4, 32 = 86.98; p < 0.001). Post-hoccomparisons (Tukey’s b)
indicated that P rats given 10 and 50 μM nicotine received more self-infusions than P rats
given aCSF or 1 μM nicotine (Fig. 2; right panel). In addition, post-hoc comparisons
indicated that P rats given 100 μM nicotine received more self-infusions compared to all
other nicotine concentrations. For Wistar rats, there was also a significant effect of nicotine
concentration (F6, 24 = 4.7; p = 0.009) on the average number of infusions. Post-hoc
comparisons (Tukey’s b) indicated that the number of infusions obtained by Wistar rats
given 50 and 100 μM nicotine were significantly higher than infusions of aCSF, and that
Wistar rats given 50 μM nicotine received significantly more infusions than Wistar rats
given 10 μM nicotine (Fig. 2; left panel). There was no difference in the number of aCSF
infusions between P and Wistar rats (F1,12 = 0.98: p = 0.34). In contrast, P rats given 10, 50,
and 100 μM nicotine received significantly more self-infusions than Wistar rats at each of
the concentrations (F values > 7.1; p values < 0.019).
Further analyses allowed for the determination of lever discrimination during acquisition,
extinction and reinstatement. The overall analysis revealed a significant session X lever X
nicotine concentration interaction term (F24, 120 = 3.2; p < 0.001). For P rats given aCSF or
1 μM nicotine into the pVTA, there were no significant differences in responses on the
active and inactive levers across the 7 sessions (all p values > 0.172; data not shown). In
contrast, P rats self-infusing 10, 50, and 100 μM nicotine into the pVTA responded
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significantly more on the active than inactive lever (all p values < 0.003) during sessions 1-4
and session 7 (Fig. 3, right panel), but not during aCSF substitution (session 5 and 6; Fig. 3,
right panel).
To determine if active lever responses were extinguished during aCSF substitution (sessions
5 and 6), a repeated measure ANOVA was performed for P rats given 10, 50 and 100 μM
nicotine. For active lever responding, there were significant differences between sessions
4-6 (p values < 0.001; Fig. 3, right panel). In each separate group of rats, t-tests indicated a
significant reduction in active lever responses between sessions 4 and 5, and between
sessions 4 and 6 (p values < 0.002; Fig. 3, right panel).
The analysis for lever discrimination for Wistar rats revealed a significant session X lever X
nicotine concentration interaction term (F36, 282 = 1.5; p < 0.001). For Wistar rats given
aCSF or 10 μM nicotine into the pVTA, there were no significant differences in responses
on the active vs. inactive lever across the 7 sessions (all p values > 0.085). In contrast,
Wistar rats self-infusing 50, 100 or 200 μM nicotine into the pVTA discriminated between
active and inactive levers (all p values < 0.04; Fig. 3, left panel and Fig. 4), which was
altered across sessions (session X lever interaction terms – all p values < 0.02). At 50 and
100 μM nicotine, lever discrimination occurred in some of the sessions between 1 and 4, but
was always observed during session 7 (Fig. 3, left panel). For 200 μM nicotine, lever
discrimination was observed during sessions 1-4 and session 7 (Fig. 4). At 400 μM nicotine
lever discrimination was only observed during sessions 4 and 7 (p values < 0.05); lever
discrimination was not observed during any session with 800 μM nicotine (p values > 0.05)
(Fig. 4).
To determine if active lever responding and the number of self-infusions were extinguished
during aCSF substitution (sessions 5 and 6), a repeated measure ANOVA was performed for
Wistar rats self-infusing 50 and 100 μM nicotine into the pVTA (Fig. 3, left panel). For
active lever responding and number of self-infusions, there were significant across sessions
4 through 6 (p values < 0.037). For Wistar rats self-administering 100 (Fig. 3, left panel) and
200 μM nicotine (Fig. 4), t-tests performed indicated a significant reduction in both
infusions and active lever responses between sessions 4 and 5, and between sessions 4 and 6
(p values < 0.042). A reduction in responding in Wistar rats self-administering 50 μM
nicotine was only observed during session 6 (Fig. 3, left panel).
Co-infusion of 5HT3 antagonists with Nicotine
The effects of co-infusion of LY-278,584 with nicotine were determined by performing a
repeated measure ANOVA on number of responses on the active lever, as a function of
session and dose of LY-278,584. The overall analysis indicated a significant session x dose
interaction term (F6,7 = 6.54; p = 0.013; Fig. 5). Prior to co-infusion, Wistar rats readily
responded on the active lever for 200 μM nicotine, as evident by lever discrimination during
sessions 2-4 (p values < 0.041). The addition of 100 μM LY-278,584 did not alter responses
on the active lever for 200 μM nicotine (F6,2 = 0.48; p = 0.82; Fig. 5, upper panel). In
contrast, co-infusion of 200 μM LY-278,584 did reduce responding on the active lever for
200 μM nicotine (F6,2 = 18.45; p = 0.047; Fig. 5, lower panel). T-tests indicated a significant
reduction in active lever responses between sessions 4 vs 5, and between sessions 4 vs 6 (p
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values < 0.03). Responding on the active lever returned during session 7 when only 200 μM
nicotine was given (p = 0.038).
With co-administration of zacopride, the overall analysis indicated a significant effect of
session (F6,6 = 6.65; p = 0.018; Fig. 6). Prior to addition of the antagonist, Wistar rats
readily self-infused 200 μM nicotine, as evidenced by higher responding on the active than
inactive lever during sessions 2-4 (p values < 0.026). Co-infusion of 10 μM zacopride
reduced 200 μM nicotine self-infusions only during the 2nd co-administration session
(sessions 6; p < 0.01; Fig. 6, upper panel). Co-infusion of 100 μM zacopride reduced 200
μM nicotine self-administration during both sessions (5 and 6; p values < 0.001; Fig. 6,
lower panel). Responses on the active lever returned during session 7 when only 200 μM
nicotine was given (p values < 0.013).
DISCUSSION
The major findings of this study are that the pVTA of P rats is more sensitive than the pVTA
of Wistar rats to the reinforcing effects of nicotine, and that activation of local 5-HT3
receptors may be needed to maintain these effects. The current results support the hypothesis
that there is an association between selective breeding for alcohol preference and enhanced
sensitivity to the reinforcing effects of nicotine. This was indicated by the findings that P
rats will self-infuse lower concentrations of nicotine (Fig. 2) and will readily discriminate
the active from the inactive lever at 10 μM nicotine (Fig. 3, right panel), whereas Wistar rats
self-administer this concentration of nicotine at the same level as aCSF and do not
demonstrate lever discrimination at this dose. Moreover, P rats received more self-infusions
of nicotine than did Wistar rats at the 10, 50 and 100 μM concentrations of nicotine (Fig. 2).
The combination of increased responsiveness to the effects of nicotine and higher number of
self-infusions suggest that nicotine may be a stronger reinforcer in the pVTA of P rats than
Wistar rats. Rodd et al. (2004) reported similar differences in sensitivity of the pVTA
between P and Wistar rats for EtOH. Collectively, these findings support the idea that there
may be a genetic linkage between selective breeding for high alcohol preference and
increased sensitivity of the pVTA to the reinforcing actions of drugs of abuse.
The dose effects of nicotine self-infusions into the pVTA of Wistar rats exhibited an
inverted ‘U-shaped’ response, with active lever responding and discrimination at 50 to 200
μM nicotine but not at the 10 or above 400 μM (Figs. 3 and 4). A similar inverted ‘U-
shaped’ dose-response plot was demonstrated for EtOH self-infusions into the pVTA of
Wistar rats (Rodd-Henricks et al. 2000). The lack of response at the high concentrations
could indicate non-specific effects of nicotine that reduced DA neuronal activity and
inhibited self-infusions. The lack of a dose-response effect between 50 and 200 μM nicotine
into the pVTA suggests that these are maximal concentrations and that lower doses should
have also be tested with the Wistar rats.
The present results are compatible with published data indicating that nicotine can be self-
infused into the pVTA of Wistar rats (Ikemoto et al., 2006). This latter study indicated that
25 mM nicotine was reliable self-infused, which is approximately 500-fold higher than the
present results (Fig. 2). The concentrations of nicotine used in the current experiments fall
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within the physiological realm of human smokers (15-150 ng/ml; Benowitz and Jacob,
1984) and of P rats orally consuming nicotine (Hauser et al., in press). The reasons for the
difference between Ikemoto et al. (2006) and the current experiment are difficult to
understand, but may be due to a combination of factors, e.g., source of Wistar rats
(Indianapolis Harlan vs. Virginia Harlan), the micro-infusion procedure (EMIT unit in
present study vs. micro-infusion pump), placements within the pVTA, and general operant
procedure. Recent data collected for other experiments have indicated a similar dose-
response curve between male and female Wistar rats for nicotine ICSA into the pVTA
(Rodd et al., submitted), therefore gender differences do not appear to be involved in the
discrepancy. It is not possible with the available information to determine which factor or
factors could contribute to the differences observed between the current study and the study
of Ikemoto et al. (2006).
The present study indicated that co-administration of 5-HT3 antagonists reduced responding
on the active lever, suggesting that activation of local 5-HT3 receptors are involved in
mediating the reinforcing effects of nicotine within the pVTA (Figs. 5 and 6). Previous
studies indicated that 5-HT3 receptor antagonists reduced the local self-infusions of EtOH
(Rodd-Henricks et al., 2003) and cocaine (Rodd et al., 2005a) in the pVTA, suggesting that
5-HT3 receptors may be important regulators of the brain reward system’s response to drugs
of abuse. However, there are some differences in the effectiveness of LY-278,584 and
zacopride to reduce EtOH self-infusions into the pVTA of Wistar rats (Rodd-Henricks et al.
2003) and their effectiveness in reducing nicotine self-infusions into the pVTA of Wistar
rats in the present study (Figs. 5 and 6). Lower doses of LY-278,584 (25 μM) inhibited
EtOH self-infusions whereas a 100 μM concentration was not effective in reducing nicotine
self-infusions (Fig. 5). On the other hand, in the case of zacopride, the 10 μM concentration
was almost equally effective in reducing the self-infusion of EtOH (Rodd-Henricks et al.
2003) and nicotine (Fig. 6). The differences in the effectiveness of the 2 antagonists to
reduce EtOH vs. nicotine self-infusions may be a result of the differences in their relative
receptor specificities (Klein et al. 1994), and that different receptor mechanisms underlie the
rewarding actions of EtOH and nicotine within the pVTA.
In another study, it was demonstrated that activation of 5-HT3 receptors, with a 5-HT3
agonist, in the pVTA produced reinforcing effects (Rodd et al., 2007). Furthermore, the
pVTA of the P rat was more sensitive than the pVTA of Wistar rats to the reinforcing effects
of the 5-HT3 agonist (Rodd et al., 2007). These latter results suggest that the difference in
sensitivity of the pVTA to the reinforcing effects of nicotine between P and Wistar rats may
be due to differences in 5-HT3 receptors between the two rat strains. In support of this idea,
a microdialysis study (Liu et al., 2006) indicated that the pVTA of the P rat was more
sensitive than the pVTA of the Wistar rat to the stimulating effects of a 5-HT3 agonist on the
somatodendritic release of dopamine, suggesting differences in the number of 5-HT3
receptors and/or the functional properties of the 5-HT3 receptors between P and Wistar rats.
It is likely that both 5-HT3 antagonists are acting at 5-HT3 receptors to reduce the excitatory
tone of VTA DA neurons (Liu et al., 2006), and thereby prevent the self-infusion of
nicotine.
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The reduction in responding on the active lever when the 5-HT3 antagonists were co-infused
with nicotine is not likely due to a motor impairing effect. Administration of 5-HT3 receptor
antagonists, at concentrations used in the present, into the pVTA did not result in a reduction
of locomotor activity (Rodd-Henricks et al., 2003) or alter oral operant self-administration
for saccharin (Rodd et al., 2010). Moreover, a previous study indicated that co-infusion of a
5-HT3 antagonist (ICS 205,930), at concentrations as high as 400 μM, did not alter
responses on the active lever for the self-infusion of acetaldehyde into the pVTA (Rodd et
al., 2005b).
Mechanisms underlying the reinforcing effects of nicotine within the pVTA may involve the
interaction of nicotine at α4β2, α6β2 and α7 receptors on DA cell bodies, and/or on
excitatory nerve terminals acting on DA neurons. The expression of nicotinic receptors is
greater in the pVTA compared to anterior VTA or the tail of VTA (Zhao-Shea et al. 2011).
The α4 and α6 nicotinic receptors have been shown to be necessary for nicotine-induced DA
neuron activity in pVTA (Zhao-Shea et al. 2011; Gotti et al., 2010). It has also been reported
that α4 nicotinic receptors and 5-HT3 receptors co-exist on striatal nerve terminals
(Dougherty and Nichols, 2009; Nayak et al., 2000), although it is not known if a similar co-
existence also occurs within the VTA. Prolonged DA neurotransmission may be due to α7
nicotinic receptors on the presynaptic glutamate terminals, which do not desensitize to
nicotine as rapidly as α4 and α6 receptors, but continue to enhance glutamatergic excitation
in the presence of nicotine (Pidoplichko et al., 2004). Therefore presence of the α7 nicotinic
receptor on excitatory glutamatergic terminals (Albuquerque et al., 2009; Gotti and Clementi
2004; Nayak et al., 2000; Wonnacott 1997), and activation of these receptors by nicotine
could result in stimulation of DA neurons and promotion of rewarding behavior in pVTA. 5-
HT3 receptors are also involved in mediating the release of glutamate (Dong et al., 2009). It
is possible that the activation of both nicotinic and 5-HT3 receptors may be needed to
increase the release of glutamate in the pVTA and that the inhibition of one or both
receptors by the 5-HT3 receptor antagonists could prevent glutamate release and the
resulting increased activation of VTA DA neurons.
In conclusion, the results of the present study suggest an association between selective
breeding for high alcohol preference and enhanced sensitivity of the pVTA to the
reinforcing effects of nicotine. Moreover, the current results provide additional support that
there is a strong genetic influence on the pVTA response to the rewarding actions of drugs
of abuse. Serotonin via activation of 5-HT3 receptors may be needed to maintain the
excitatory tone of VTA DA neurons to support the reinforcing actions of nicotine within the
pVTA. The biological basis for the altered sensitivity to the reinforcing actions of drugs of
abuse within the pVTA as the result of selection for high alcohol preference may be
predicated on differences in 5-HT3 receptors (e.g., cation-π interaction).
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Fig. 1.
Illustrated is a representation of the placements of injection sites within the posterior VTA
(defined as –5.4 to –6.0 mm Bregma) of Wistar rats (left, squares) and P rats (right, circles)
self-administering aCSF or various concentrations of nicotine.
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Fig. 2.
The average number of infusions (± SEM) across the initial 4 sessions (acquisition) by
Wistar and P rats as a function of infusate concentration (0 to 100 μM) with cannula
placements in the posterior VTA. Asterisks indicate infusions significantly higher than aCSF
and 10μM nicotine infusions; plus symbols indicate significantly higher values compared to
aCSF, 1 μM nicotine and to the number of infusions by Wistar rats (p < 0.05; Tukey’s b
post-hoc).
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Fig. 3.
The number of active and inactive lever presses (means ± SEM) for Wistar and P rats self-
administering 10, 50 or 100 μM nicotine into the posterior VTA during sessions 1-4, aCSF
for sessions 5 and 6, and the original infusate during session 7. Asterisks represent
significant (p<0.05; Tukey’s) differences from responding observed for rats self-infusing
aCSF, and responding on the active lever significantly differed (p < 0.05) from responding
on the inactive lever (determined by one-way ANOVAs performed on individual sessions
contrasting active and inactive lever presses). Plus symbols indicated differences from
responding observed for rats self-infusing aCSF, responses on the active lever significantly
differed (p < 0.05) from responding on the inactive lever and higher responding on active
lever by P rats compared to Wistar rats.
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Fig. 4.
The number of active and inactive lever presses (means ± SEM) for Wistar rats self-infusing
200, 400 or 800 μM nicotine into the posterior VTA during sessions 1-4, aCSF for sessions
5 and 6, and the original infusate during session 7. Asterisks represent significant (p<0.05;
Tukey’s) difference from responding observed for rats self-infusing aCSF, and responses on
the active lever significantly differed (p < 0.05) from responding on the inactive lever.
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Fig. 5.
Effects of 100 and 200 μM LY-278,584 on responding for the self-infusion of 200 μM
nicotine into the posterior VTA of Wistar rats. For the first 4 sessions, 200 μM nicotine
alone was given. In sessions 5 and 6, LY-278,584 was co-infused with 200 μM nicotine. In
session 7, only 200 μM nicotine was given. Data are the means ± S.E.M. Asterisks indicate
that responses on the active lever were significantly higher than responses on the inactive
lever for that session (p < 0.05). Plus symbols indicate that LY-278,584 significantly
reduced responding for 200μM nicotine during sessions 5 and 6 compared to session 4 (p <
0.05).
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Fig. 6.
Effects of 10 and 100 μM zacopride on responding for the self-infusion of 200 μM nicotine
into the posterior VTA of Wistar rats. For the first 4 sessions, 200 μM nicotine alone was
given. In sessions 5 and 6, zacopride was co-infused with 200 μM nicotine. In session 7,
only 200 μM nicotine was given. Data are the means ± S.E.M. Asterisks indicate that
responses on the active lever were significantly higher than responses on the inactive lever
for that session (p < 0.05). Plus symbols indicate that zacopride significantly reduced
responding for 200μM nicotine during sessions 5 and/or 6 compared to session 4 (p < 0.05).
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